Mercer Global Advisors
MYGN icon

Mercer Global Advisors’s Myriad Genetics MYGN Stock Holding History

Mercer Global Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$417K Buy
72,956
+37,051
+103% +$168K ﹤0.01% 2471
2026
Q1 		$162K Buy
35,905
+9,019
+34% +$47K ﹤0.01% 2905
2025
Q4 		$165K Buy
26,886
+10,359
+63% +$75.1K ﹤0.01% 2619
2025
Q3 		$119K Buy
+16,527
New +$98.1K ﹤0.01% 2492

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mercer Global Advisors's MYGN Position: Q2 2026 in Review

Mercer Global Advisors increased its Myriad Genetics (MYGN) stake by 103% in Q2 2026, buying an estimated $168K and bringing the position to 72,956 shares worth $417K. The position accounts for ﹤0.01% of the portfolio, ranked #2471.

Mercer Global Advisors first reported a position in MYGN in Q3 2025 and has held it in 4 quarters since. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Mercer Global Advisors held 72,956 shares of Myriad Genetics worth $417K as of Q2 2026.
  • Mercer Global Advisors bought 37,051 Myriad Genetics shares in Q2 2026, an estimated $168K.
  • Myriad Genetics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #2471 holding.
  • Mercer Global Advisors first reported a position in Myriad Genetics in Q3 2025 and has held it in 4 quarters since.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.